Scope of Things

Ardy Arianpour on Seqster’s Patient-Centered Healthcare Movement

May 2, 2023


When Seqster was first founded in 2016, co-founder Ardy Arianpour had a lot of experience in next-gen sequencing and a vision for how consumers could control their health information. Arianpour envisioned a place where anyone can bring all their health data together in one place and share it on their terms. Since then, Arianpour says he has found many parts of the business challenging. There have been shifts in the business model over time, which began as direct-to-consumer. He credits Seqster’s 2020 agreement with Takeda Pharmaceuticals as a tipping point. Now, with several pharma partnerships to boast, Seqster is more than a company, Arianpour insists to host, Deborah Borfitz, in the latest Scope of Things podcast. “This is a movement.”

Ardy Arianpour, CEO and Co-Founder, Seqster
Ardy Arianpour is CEO & Co-Founder of SEQSTER the leading healthcare technology company that puts the patient at the center of all their health data. He is a visionary health tech executive with 20+ years driving innovation in biotech, life sciences and digital health. Prior to starting SEQSTER, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics, and served as SVP of Ambry Genetics, which sold to Konica in 2017 for $1 Billion. Ardy received his BS in Biological Sciences from UC Irvine and an MBA from Marshall Goldsmith School of Management. He was a Medical, Marketing, and Media’s (MM&M) Top 40 Healthcare Transformer and San Diego Business Journal 40 under 40. Ardy is on the Digital Health Advisory Board of UCSD and Faculty for NextMed.Health.